ASX Announcement Quarterly Activities Report & Appendix 4C Key Highlights • Advanced DEP® HER2-Lu towards the first-in-human Phase 1 clinical study, submitting the Clinical Trial Application in Europe and completing manufacture of the non- radiolabelled clinical material. • Following quarter...